Condition: Diabetes · Diabetes Mellitus · Type 1 Diabetes · Sponsor: Insulet Corporation
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| CHU Angers | Angers, France | — |
| CHU Besançon - Hôpital de Jean Minjoz | Besançon, France | — |
| APHP Hopital Avicenne | Bobigny, France | — |
| CHU Bordeaux - Hôpital Pellegrin | Bordeaux, France | — |
| CHU Bordeaux - Hôpital St-André | Bordeaux, France | — |
| CHU BresCHU Brest - Hôpital de la Cavale Blanchet - Hôpital de la Cavale Blanche | Brest, France | — |
| Hôpital Femme Mère Enfant | Bron, France | — |
| Centre Hospitalier Sud Francilien | Corbeil-Essonnes, France | — |
| CHU Dijon - Hôpital François MitterrandCHU Dijon - Hôpital François Mitterrand | Dijon, France | — |
| GH La Rochelle-Ré-Aunis - Hôpital Saint Louis | La Rochelle, France | — |
| APHP Hôpital Bicêtre | Le Kremlin-Bicêtre, France | — |
| Diab-eCare | Lyon, France | — |
+ 12 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.